Anuh Pharma ‘s Q2 Update: Profit Grows by 8.75% YoY

The comprehensive analytics outlining the performance and outlook of Anuh Pharma Ltd.,‘s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at Anuh Pharma Ltd.,’s financial performance for the Q2(Sep 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 10.98 %. However, it did see a marginal increase of 20.34 % from the previous quarter. Expenses ticked up slightly by 17.07 % quarter-on-quarter, aligning with the annual rise of 13.31 %. Operating profit, while down -6.07 % compared to last year, faced a quarter-on-quarter increase of 59.6 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -1.84 %, but an expansion of 2.51 % sequentially. Other income fell by -8.58 % compared to the last quarter, despite an annual growth of 58.21 %. Interest expenses surged remarkably by 14.29 % from the previous quarter, yet the year-over-year increase remains at a moderate 77.78 %. Depreciation costs climbed by 2.13 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -10.7 %. Profit before tax grew annually by 1.79 % but saw an increase from the preceding quarter by 48.25 %.
Tax expenses as a percentage of profits decreased slightly by -5.28 % compared to last year, with a more notable quarter-on-quarter decrease of -5.16 %. Net profit rose by 8.75 % year-on-year but experienced a 58.15 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 8.7 % but a quarterly rise of 57.89 %. In summary, Anuh Pharma Ltd.,’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Anuh Pharma Ltd.,’s 2024-25(Q2) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 10.98 % year-on-year growth, however, there was a minor increase of 20.34 % from the previous quarter. Expenses rose by 13.31 % compared to the previous year, with a 17.07 % increase quarter-on-quarter. Operating Profit dropped by -6.07 % annually, and saw a 59.6 % increase from the last quarter.
Net Profit showed yearly increase of 8.75 %, and experienced a 58.15 % increase from the previous quarter. Earnings Per Share (EPS) rose by 8.7 % annually, however rose by 57.89 % compared to the last quarter. In essence, while Anuh Pharma Ltd., exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.